Synthetic Biologics Inc (NYSE: SYN) today announced that patient medicating and scrutiny has been accomplished in its Stage 1, exposed label, single-ascending dose (SAD) scientific pilot of SYN-020 intestinal alkaline phosphatase (IAP). Stage 1 SAD study registered 24 fit grownup helpers The Stage 1 SAD study registered 24 fit adult […]